Abstract library

1 results for "Contente".
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês